Clinical trial
A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
NCT07425821 is registered in ClinicalTrials.gov with International AIDS Vaccine Initiative as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
- Lead sponsor
- International AIDS Vaccine Initiative
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- March 27, 2026
- Completion date
- October 31, 2027
- Enrollment
- 112 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.